Brief: CNS Pharmaceuticals Announces FDA Filing Of IND For Its Brain Cancer Drug Berubicin
17/11/2020 13:01
Nov 17 (Reuters) - CNS Pharmaceuticals Inc CNSP.O :
* CNS PHARMACEUTICALS ANNOUNCES FDA FILING OF IND FOR ITS
BRAIN
CANCER DRUG BERUBICIN
* CNS PHARMACEUTICALS INC - EXPECTS TO INITIATE PHASE 2
TRIAL
DURING Q1 OF 2021 FOR ITS BRAIN CANCER DRUG BERUBICIN
Source text for Eikon: ID:nPn7kPyFMa
Further company coverage: CNSP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CNS Pharmaceuticals
See all newsCNS Pharmaceuticals Q2 net loss widens, cash rises after financing
CNS Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
Brief: Cns Pharmaceuticals Appoints Rami Levin As CEO Effective Jan 1, 2026